s-109802 for post-stroke spasticity; s-151128 for chronic pain; s-588210 and s-531011 for solid tumor; s-309309 for obesity; bpn14770 for alzheimer’s disease and fragile x syndrome; s-588410 for bladder cancer; s-488210 for head and neck squamous cell carcinoma; s-005151 for acute isch...
In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer’s disease and fragile X syndrome; S-588410 for bladder cancer; S-...
Vehicle S-309309 reduced body weight and visceral fat weight** following decrease in food intake 43** Epididymal fat, retroperitoneal fat, mesenteric fat S-309309: Effect on Increased Energy Expenditure 1 0 0 -1 Diet-induced obese mice (60% kcal/fat) Vehicle S-309309 7 14 21 0 1 2 3 ...
Pain/CNS S-151128 Chronic pain Japan Ⅰ New ingredientMetabolic disorder ADR-001 Decompensated liver cirrhosis Japan Ⅰ Ⅱ New ingredientMetabolic disorder S-723595 Type 2 diabetes New Zealand Ⅰ Ⅱ New ingredientMetabolic disorder S-309309 Obesity USA Ⅰ Ⅱ New ingredient...